Yang de Marinis

Yang de Marinis is an Associate Professor at the Department of Clinical Sciences, Lund University, Sweden, with additional roles as Chair Professor at Shandong University (China), Visiting Scientist at the University of Oxford (UK), and Board Member at Diabetes Sverige. Her primary research affiliations include EXODIAB (Excellence of Diabetes Research in Sweden) and EpiHealth (Epidemiology for Health).

Her research integrates molecular biology, epidemiology, and computational methods to investigate epigenetics and genetics of diabetes complications, biomarker diagnostics, and metabolic disorder regulation mechanisms. She employs cutting-edge technologies including genome-wide chromatin immunoprecipitation sequencing, CRISPR/Cas9 genome engineering, and AI-driven machine learning on clinical cohort studies, with strong emphasis on translational applications for diabetes and cardiometabolic diseases.

Recent publications (2021-2025) reveal interdisciplinary innovation spanning molecular virology (mRNA vaccine studies), epigenomic profiling in diabetes, and AI-based predictive modeling for stroke and microbe-disease associations, demonstrating consistent integration of wet-lab techniques with computational analytics.

Dr. de Marinis founded MedTech company Lundoch Diagnostics in 2020 (recognized among Sweden's top 33 young tech companies in 2022), led the SARS-CoV-2 antibody response project (2020), and actively engages in public outreach through initiatives like the 2017 Diabeteskväll event, reflecting commitment to both academic research and real-world health impact.